More recently, immune checkpoint inhibitors, such as PD-1 and programmed death ligand 1 (PD-L1) inhibitors, have shown a potential therapeutic advantage for patients with advanced HCC (26). The gene discussed is CD274; the disease is hepatocellular carcinoma.